OXFORD PHARMS
GenericsOXFORD PHARMS is a generic drug manufacturer focused on Neurology, Cardiovascular, Immunology.
OXFORD PHARMS's Key Drugs
OXFORD PHARMS's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
OXFORD PHARMS's Recent FDA Approvals
New NDA/BLA approvals for OXFORD PHARMS over the last two years — novel drugs only, excluding generics and label supplements.
OXFORD PHARMS's Therapeutic Areas
OXFORD PHARMS's approved drugs and pipeline span 5 therapeutic areas, led by Neurology and Cardiovascular, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
OXFORD PHARMS's Top Competitors
OXFORD PHARMS's closest competitors by therapeutic-area and drug-target overlap include Takeda, Novo Nordisk, and Johnson & Johnson. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
OXFORD PHARMS Pipeline Snapshot
Active clinical trials for OXFORD PHARMS across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Neurology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 1971-05-21
- Latest
- 2026-04-15
- Applications
- 33